01 6Genvoya
02 5Prezista/Prezcobix/Rezolsta/Symtuza
03 2Revenue share - Symtuza
04 8Stribild
05 3Symtuza
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,338
2019 Revenue in Millions : 3,931
Growth (%) : -15
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 196
2019 Revenue in Millions : 369
Growth (%) : -47
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 488
2019 Revenue in Millions : 379
Growth (%) : 29
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 2,184
2019 Revenue in Millions : 2,110
Growth (%) : 4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 189
2020 Revenue in Millions : 196
Growth (%) : -4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 531
2020 Revenue in Millions : 488
Growth (%) : 9
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 2,083
2020 Revenue in Millions : 2,184
Growth (%) : -5
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 2,879
2020 Revenue in Millions : 3,338
Growth (%) : -14
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 2,404
2021 Revenue in Millions : 2,879
Growth (%) : -16
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 1,943
2021 Revenue in Millions : 2,083
Growth (%) : -7
LOOKING FOR A SUPPLIER?